The war of words between GlaxoSmithKline and critics of the firm’s oral diabetes drug escalated yesterday, as the marketer took additional steps to shore up confidence in Avandia.

Lilly and Amylin launched “Let’s Talk,” a Byetta-branded diabetes awareness effort fronted by Delta Burke.

A triumvirate of companies is seeking pharma sponsors for a disease awareness campaign centered on Black churches.

For healthcare PR professionals, our ongoing journey of change through the healthcare industry involves technology and leadership in ways that were never thought of a few short years ago.

What would happen if you booked a hotel conference room and filled it with senior FDA officials, top academics, threw in a some fashionable healthcare policy experts and spiced it up with a couple of healthcare journalists, pharmaceutical executives and patient advocates?

Edelman named Shellie Winkler EVP, corporate health in the Eastern region.

Publicly held Huntsworth PLC, based in London, has purchased Dorland Global Corp., for $20.7 million in cash, extending the reach of its healthcare division into the US market.

The notion that the industry is capable of turning around its negative public perception suddenly looks more realistic. Matthew Arnold reports on some encouraging results in the annual Edelman Trust Barometer

Many pharmas have taken a haughty tone with analysts and investors. The Street’s not taking it anymore. It’s time to crank up the humility and bring the transparency.

An inability to consistently measure the effect of PR—and therefore demonstrate its value—has long been the Achilles heel of the communications exec looking for a seat at the table. Matthew Arnold reports on some encouraging developments